|
J Biol Chem, Vol. 275, Issue 11, 8126-8132, March 17, 2000
Cloning and Function of Rabbit Peroxisome Proliferator-activated
Receptor / in Mature Osteoclasts*
Hiroshi
Mano §,
Chiharu
Kimura¶,
Yukio
Fujisawa¶,
Takashi
Kameda ,
Mikiko
Watanabe-Mano ,
Hironori
Kaneko ,
Toshio
Kaneda ,
Yoshiyuki
Hakeda , and
Masayoshi
Kumegawa
From the Department of Oral Anatomy, Meikai
University School of Dentistry, 1-1 Keyakidai, Sakado, Saitama 350-02, Japan, the § Department of Bioscience, Faculty of Applied
Bioscience, Tokyo University of Agriculture, 1-1-1 Sakuragaoka,
Setagaya, Tokyo 156, Japan, and the ¶ Molecular Pharmacology
Laboratory, Pharmaceutical Research Division, Pharmaceutical Group,
Takeda Chemical Industries, Ltd., 2-17-85 Juso-Honmachi,
Yodogawa, Osaka 532, Japan
 |
ABSTRACT |
Osteoclasts modulate bone resorption under
physiological and pathological conditions. Previously, we showed that
both estrogens and retinoids regulated osteoclastic bone resorption and
postulated that such regulation was directly mediated through their
cognate receptors expressed in mature osteoclasts. In this study, we
searched for expression of other members of the nuclear hormone
receptor superfamily in osteoclasts. Using the low stringency
homologous hybridization method, we isolated the peroxisome
proliferator-activated receptor / (PPAR / ) cDNA from
mature rabbit osteoclasts. Northern blot analysis showed that
PPAR / mRNA was highly expressed in highly enriched rabbit
osteoclasts. Carbaprostacyclin, a prostacyclin analogue known to be a
ligand for PPAR / , significantly induced both bone-resorbing
activities of isolated mature rabbit osteoclasts and mRNA
expression of the cathepsin K, carbonic anhydrase type II, and
tartrate-resistant acid phosphatase genes in these cells. Moreover, the
carbaprostacyclin-induced bone resorption was completely blocked by an
antisense phosphothiorate oligodeoxynucleotide of PPAR / but not
by the sense phosphothiorate oligodeoxynucleotide of the same DNA
sequence. Our results suggest that PPAR / may be involved in
direct modulation of osteoclastic bone resorption.
 |
INTRODUCTION |
Mature osteoclasts are differentiated from hemopoietic stem cells
and fuse each other into multinucleate giant cells. These cells are
characterized by a combination of some unique properties. They possess
tartrate-resistant acid phosphatase
(TRAP)1 activity, an
abundance of cathepsin K, and highly developed ion transport systems
(1, 2). Mature osteoclasts are involved in bone metabolism, especially
they resorb mineralized bone surfaces under both physiological and
pathological conditions (3).
Much evidence obtained from in vitro studies has
demonstrated that the differentiation of osteoclasts is controlled by
various factors, such as vitamin D3, osteoclast
differentiation factor, osteoclastogenesis inhibitory factor,
macrophage colony-stimulating factor, and parathyroid hormone (4-7).
The osteoclast is also active in postmenopausal osteoporosis (bone
loss), a major health problem (2). Estrogen deficiency has long been
recognized as a cause of postmenopausal osteoporosis, and estrogen
replacement therapy is an effective treatment for the prevention of
bone loss. Research has shown that estrogen loss promotes interleukin-6
secretion in nonosteoclastic cells and that interleukin-6 up-regulates
osteoclast differentiation and formation (8, 9). However, the function and metabolism of fully mature osteoclasts remain unclear, especially at the molecular level, because of the difficulty in obtaining large
quantities of highly enriched osteoclasts for use in such in
vitro studies.
For assessment of the bone-resorbing activity of mature osteoclasts, it
would be desirable to have a cell suspension consisting of highly
enriched mature osteoclasts that could be cultured on a mineralized
substratum such as a bone or dentine slice. Previously, we succeeded in
isolating the highly enriched mature osteoclasts by treating
unfractionated rabbit bone cells cultured on plastic dishes with
Pronase E/EDTA (10). However, it was impossible to detach these
isolated osteoclasts from the substratum in order to prepare the cell
suspension. Recently, we established a method to isolate mature rabbit
osteoclasts with high purity (>99%) from a collagen gel to obtain
them in suspension form for subsequent incubation on dentine slices
(11). Using these highly enriched mature osteoclasts, we clarified that
estrogen directly inhibited bone resorption and cathepsin K gene
expression and induced osteoclastic apoptosis through estrogen receptor
(12, 13). Moreover, we demonstrated that retinoids activated both
osteoclastic bone resorption and gene expression of cathepsin K, and of
retinoic acid receptor and retinoid X receptor were expressed
in mature osteoclasts (14).
Receptors for steroid hormones, retinoids, vitamin D, thyroid hormone,
and prostanoids comprise a superfamily of regulatory proteins that are
structurally and functionally related. Previous studies showed that
members of the nuclear hormone receptor superfamily shared high
homology in their amino acid sequences, with the highest homology
conserved among their DNA binding domains. Nuclear hormone receptors
bind to cis-acting elements in the promoters of their target
genes and modulate gene expression in response to their ligands (15,
16). Molecular cloning studies revealed both new nuclear receptors and
orphan nuclear receptors, the natural ligands of which remain unclear.
These findings suggest potentially novel signal pathways in the body
(17).
In order to examine the possibility of such a novel signal pathway in
mature osteoclasts, we screened for nuclear hormone receptors in a
rabbit mature osteoclast cDNA library by taking advantage of the
structural homology of the DNA-binding domain of nuclear receptors.
Thereby, the rabbit cDNA of peroxisome proliferator-activated receptor (PPAR) / was cloned from this cDNA library.
PPAR is known to be activated by arachidonic metabolites. Three types
of PPAR are now known to exist, i.e. PPAR , PPAR , and PPAR / . PPAR is abundantly expressed in liver tissue and is activated by leukotriene B4 (18). PPAR is abundantly
expressed in adipose tissue and is activated by 15-deoxy-prostaglandin
J2, 9- and 13-hydroxyoctadecadienoic acid, and
thiazolidinediones (19, 20). The distribution of PPAR / mRNA
is the most widespread, and prostacyclin and its analogues activate
PPAR / (21, 22). Although PPAR plays a principal role in
adipogenesis, it is unclear what functions PPAR and PPAR / have
in the body.
Here we demonstrate the abundant expression of PPAR / mRNA in
mature osteoclasts and the activation of osteoclastic functions such as
bone resorption and osteoclastic gene expression by a ligand of
PPAR / . Moreover, antisense S-ODN for PPAR / blocked this
activation in mature osteoclasts. These results suggest that in part
PPAR / plays a role in osteoclastic bone resorption.
 |
MATERIALS AND METHODS |
Isolation of Mature Osteoclasts from Rabbit Long
Bones--
Unfractionated bone cells were isolated from tibiae,
femora, humeri, ulnae, and radii of 10-day-old rabbits. After the
removal of soft tissues, these bones were minced in -minimum
essential medium ( -MEM). Cells were dissociated from the bone
fragments by sedimentation under normal gravity for 1 min. The
supernatant was used as unfractionated bone cells (crude osteoclasts).
These cells were plated in 10-cm tissue culture dishes coated with
0.24% collagen gel (Nitta Gelatin, Tokyo, Japan) in -MEM
supplemented with 5% fetal bovine serum (FBS) and incubated for 3 h. Nonosteoclastic cells were then removed from the gel by sequential
treatment with 0.001% Pronase E, 0.02% EDTA, and 0.01% collagenase.
The remaining osteoclasts were subsequently collected by treatment with
0.1% collagenase. After having been washed with calcium- and
magnesium-free phosphate-buffered saline (PBS), the isolated
osteoclasts were replated onto dentine slices in phenol red-free
-MEM supplemented with 0.1% bovine serum albumin for generating
cDNA libraries and used in the pit assay (11).
The purity of the isolated osteoclasts was confirmed by microscopic
scoring of TRAP-positive multinucleate cells in the presence of 50 mM L-tartrate with a leukocyte-acid-phosphatase
kit (Sigma). When TRAP-positive multinucleate cells isolated from
collagen gels were placed on dentine slices, they showed a compact and round shape, and the morphology of the cells resembled that of osteoclasts in vivo more than the cells cultured on plastic
plates (10). These TRAP-positive multinucleate cells (100 cells/culture drop) were cultured in tissue-culture dishes for 7 days to assess formation of colonies of nonosteoclastic stromal cells. Only 0.4 ± 0.49 (n = 5) colonies were formed per culture drop
after a 1-week culture. Thus, the purity of the TRAP-positive
multinucleate cells was more than 99%. When these cells were cultured
on dentine slices, resorption pits were formed around these cells as
observed under a scanning electron microscope. Transmission electron
microscopic observation revealed a ruffled border-like membrane and
clear zone on the side of these cells attached to the surface of the dentine. Thus, cells isolated from collagen gels exhibited the typical
morphology of authentic osteoclasts, and the multinucleate cells had
the ability to excavate dentine even when stromal cells were absent
from the culture. These TRAP-positive multinucleate cells were indeed
mature osteoclasts (data not shown).
Molecular Cloning of Rabbit PPAR / cDNA from Mature
Osteoclasts--
Total RNA of mature rabbit osteoclasts cultured on
dentine slices was isolated by the acid guanidium
thiocyanate-phenol-chloroform method, and the poly(A)+ RNA
was purified by using an oligo(dT) cellulose column. The cDNA
library was synthesized by using a ZAP II-cDNA Synthesis Kit
(Stratagene). An EcoT14I-HindIII DNA fragment
containing the DNA-binding domain of the human estrogen receptor (ATCC, Manassas, VA) was used as a probe to screen the ZAP II rabbit
mature osteoclast cDNA library under low stringency conditions.
Positive clones were sequenced by the dideoxy sequencing method (23,
24).
Pit Assay for Assessment of Bone-resorbing Activity of Mature
Osteoclasts--
To determine the bone-resorbing activity of the
isolated mature osteoclasts, we measured the area and number of
resorption pits formed on dentine slices by them. Briefly, isolated
osteoclasts were plated on dentine slices (circular, 6 mm in diameter)
in 96-well plates at a density of 150 isolated osteoclasts/slice/well and cultured for 1 h in phenol red-free -MEM supplemented with 0.1% bovine serum albumin at 37 °C in 10% CO2. The
medium was then replaced with fresh medium containing various
concentrations of any given reagent and cultured for 20 h (25).
The dentine slices were then brushed with a rubber policeman to remove
the cells and stained with acid hematoxylin for 5 min. The total number of pits on a dentine slice was counted under a light microscope, and
the total area of pits was quantified by densitometric analysis of
dentine slice images by videomicroscopy and using of NIH Image software
(25).
Oligodeoxynucleotide Uptake by Osteoclasts by Use of
Lipofectin--
Antisense or sense S-ODNs of PPAR / were used to
transfect mature osteoclasts by the method of Inui et al.
(26). The PPAR / antisense S-ODN was designed to be composed of 21 bases and to target the region that spans the translation start codon
of rabbit PPAR / mRNA (5'-cggaggctgctccatggctga-3'). The sense
counter part of the antisense S-ODN was also designed as a negative
control (5'-tcagccatggagcagcctccg-3'). All of these S-ODNs were
synthesized (Nippon Flour Mills Co., Ltd., Tokyo, Japan) on an
automated solid-phase nucleotide synthesizer and subsequently purified
and sterilized. A fraction of the synthesized S-ODNs was labeled with
fluorescein at the 5'-ends, in order to confirm the efficiency of S-ODN
uptake into mature osteoclasts.
Mature rabbit osteoclasts isolated by the method described above were
incubated at 37 °C in 10% CO2 on dentine slices at a concentration of 150 osteoclasts/dentine slice in 96-well tissue culture plates in the presence or absence of carbaprostacyclin (10 8 M) (Cayman Chemical Company) in -MEN
containing 5% FBS. After a 2-h incubation, the medium was exchanged
for the transfection medium, and the cells were incubated in the
presence or absence of carbaprostacyclin (10 8
M) and in the presence or absence of the antisense or sense
S-ODNs in serum-free -MEM containing 100 nM
TfxTM-50 (Promega, Madison, WI). After an 8-h incubation,
the medium in each well was exchanged for the identical medium except
that the -MEM now contained 5% FBS, and the incubation was then
continued for an additional 12 h. After the incubation, the pit
number and area were determined.
RNA Expression in Mature Osteoclasts--
Unfractionated bone
cells were plated into 90-mm tissue culture dishes with -MEM plus
5% FBS at 108 cells/dish. After an overnight culture
period, the plates were washed with PBS to remove nonadherent cells
such as hematopoietic cells. The cells were then incubated with PBS
containing 0.001% Pronase E, 0.02% EDTA for 20 min at 37 °C to
remove nonosteoclastic cells. These detached nonosteoclastic cells were
saved as the source of stromal cells. The purity of the osteoclasts in
the dishes was more than 99%.
Isolated osteoclasts on the tissue culture dishes were cultured with
carbaprostacyclin (1 × 10 8 M) for
5 h in -MEM containing 0.1% bovine serum albumin for the study
of target gene expression elicited by prostacyclin. Other cells were
cultured on dishes with antisense or sense S-ODNs and 100 nM Tfx-50 (Promega, WI) as a carrier for 20 h in
-MEM containing 0.1% bovine serum albumin for the study of the
effect of S-ODN. The total RNA was extracted from the cultured cells by
the acid guanidinium-phenol-chloroform method. Total RNA was fractionated on a formaldehyde agarose gel by electrophoresis and then
blotted onto a nylon membrane for Northern blot analysis (14).
32P-Labeled cDNA probes were prepared by the random
primer labeling procedure. The cDNAs of rabbit cathepsin K,
carbonic anhydrase type II, TARP, and matrix metalloproteinase 9 from
osteoclast cDNA library were used as hybridization probes (23, 24,
27). The mouse IP, membrane prostacyclin receptor, cDNA was obtained from S. Narumiya (Kyoto University, Kyoto, Japan). The cDNAs of mouse PPARs were a gift from R. M. Evans (The Salk Institute). A
rat glyceraldehyde-3-phosphate dehydrogenase cDNA probe was used as
a reference.
 |
RESULTS |
Molecular Cloning of the PPAR / cDNA from Mature Rabbit
Osteoclasts and mRNA Expression of PPAR Isoforms in Bone
Cells--
A 480-base pair cDNA fragment containing the human
estrogen receptor DNA binding domain was used to screen the rabbit
mature osteoclast cDNA library. Positive clones were isolated for
sequence analyses. Fig. 1A
shows the nucleotide and the deduced amino acid sequences of a positive
clone, ROCHER10. It contained a 3.4-kb insert with an open reading
frame of 1323 base pairs, encoding a polypeptide of 441 amino acids.
Sequence comparison of ROCHER10 against the GenBankTM data
base showed that ROCHER10 was most closely related to the PPAR /
gene with a 94.8% overall identity to human PPAR / , and 89.6%,
and 90.5% overall identities to the rat and mouse PPAR / , respectively (Fig. 1B). ROCHER10 shared distant homologies
of 67.1, 63.0, 64.6, and 62.9% to the human PPAR , human PPAR ,
mouse PPAR , and mouse PPAR , respectively. Thus, we concluded that clone ROCHER10 represented the rabbit PPAR / gene.

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 1.
Nucleotide and deduced amino acid sequences
of rabbit PPAR / from
mature osteoclasts. A, sequence of a rabbit PPAR /
cDNA clone (ROCHER10). The DNA and ligand-binding domains are
boxed. In-frame termination codons are indicated by
asterisks. B, schematic comparison between rabbit
PPAR / and other PPARs. Amino acid sequences were aligned by using
the program DINASIS (Hitachi Software Engineering, Co., Ltd.). The
similarity between rabbit PPAR / and other receptors is expressed
as percentage of amino acid identity.
|
|
Next, we examined the mRNA expression levels of PPAR isoforms in
rabbit bone cells and mouse clonal osteoblastic MC3T3-E1 cells by
Northern blot analysis using the rabbit PPAR / cDNA, mouse
PPAR , and mouse PPAR cDNA as probes (Fig.
2). A 3.5-kb PPAR / mRNA
transcript was detected in MC3T3-E1 cells, rabbit stromal cells, and
mature osteoclasts. The expression level of PPAR / mRNA was
most abundant in mature osteoclasts. Similar results were obtained when
a mouse PPAR / cDNA probe was used instead (data not shown).
Conversely, no PPAR or PPAR mRNA expression was detectable in
mature osteoclasts and stromal cells, whereas weak expression of
PPAR (8.5-kb) mRNA was detected in MC3T3-E1 cells. The unique
expression patterns of the PPAR isoforms in bone cells suggest that
whereas PPAR / may play a direct role in modulating mature
osteoclasts, the PPAR isoform may have specific functions in other
cell systems in bone.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 2.
Expression of PPARs mRNA in bone
cells. Total RNA was isolated from an osteoblastic cell line
(MC3T3-E1), bone stromal cells and mature osteoclasts that had been
cultured on plastic dishes in -MEM plus 10% FBS, and 20 µg of
total RNA was applied in each lane. Northern blot analysis was carried
out with 32P-labeled rabbit PPAR / or with or mouse PPAR cDNAs as probes, as described under "Materials and
Methods." The experiment was done four times, with similar results
each time.
|
|
Effect of PPAR / Ligands on Mature Osteoclasts--
With the
abundant expression of PPAR / in mature osteoclasts, we postulated
that ligands of PPAR / may play a role in regulating osteoclastic
cell function. Thus, we treated highly enriched mature osteoclasts with
carbaprostacyclin, a prostacyclin analogue, and tested them in the
osteoclastic resorption pit assay. As shown in Fig.
3, 10 9 to 10 8
M carbaprostacyclin induced an increase to approximately
2-fold greater pit area excavated by highly enriched mature osteoclasts on dentine slices. These concentrations of carbaprostacyclin did not
significantly affect the number of pits excavated. In contrast, a high
dose of carbaprostacyclin (10 5 M) decreased
the pit area excavated by mature osteoclasts. 10 7
M leukotriene B4, an agonist of both PPAR
and its own plasma membrane receptor, induced a 1.5-fold greater pit
area. WY-14643, a strong agonist of both PPAR and PPAR , did not
affect osteoclastic bone resorption significantly.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of carbaprostacyclin on osteoclastic
bone-resorbing activity. Highly enriched mature osteoclasts were
cultured on dentine slices with leukotriene B4, WY-14643,
carbaprostacyclin, or ethanol alone (as a control). Pit area and pit
numbers on dentine slices were determined as described under
"Materials and Methods." Values are means ± S.D.,
n = 4. *, p < 0.05 compared with the
control group. Data are representative of those obtained in three other
independent experiments.
|
|
Cathepsin K and matrix metalloproteinase 9 are proteases whose function
is to break down bone matrix proteins, and the carbonic anhydrase type
II gene product produces [H+] to dissolve mineralized
bone matrix. TRAP is an osteoclast marker whose function in bone
metabolism remains to be further defined. To examine whether a
PPAR / ligand would regulate the expression of genes related to
osteoclastic bone resorption, we treated highly enriched mature
osteoclasts on plastic culture dishes with carbaprostacyclin (1 × 10 8 M) for 5 h. Total RNA was extracted
from these cells, and mRNA levels of cathepsin K, carbonic
anhydrase type II, TRAP, and matrix metalloproteinase 9 were determined
by Northern blot analysis. Fig. 4 shows
that carbaprostacyclin increased the mRNA level of cathepsin K,
carbonic anhydrase type II, and TRAP but not that of matrix
metalloproteinase 9 in the mature osteoclasts. This ligand doubled the
mRNA level of cathepsin K and tripled the mRNA levels of
carbonic anhydrase type II and TRAP in the cells. However, the mRNA
level of glyceraldehyde-3-phosphate dehydrogenase was constant in the
osteoclasts treated with carbaprostacyclin.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of carbaprostacyclin on osteoclastic
gene expression. Total RNA was isolated from mature osteoclasts
that had been cultured on plastic dishes with or without
carbaprostacyclin (1 × 10 8 M) for
5 h. Twenty micrograms of total RNA was applied in each lane.
Northern blot analysis was carried out with 32P-labeled
cathepsin K, carbonic anhydrase type II (CA II), TRAP,
matrix metalloproteinase 9 (MMP9), and
glyceraldehyde-3-phosphate dehydrogenase (GPDH) cDNAs
used as probes, as described under "Materials and Methods." The
experiment was done four times, with similar results each time.
|
|
Effect of Antisense S-ODN of PPAR / on Mature
Osteoclasts--
To establish a direct role of PPAR / in
carbaprostacyclin-induced osteoclastic bone resorption, we included an
antisense S-ODN of PPAR / in the pit assay. S-ODN uptake by
osteoclasts was confirmed by incubating the cells for 24 h at
37 °C with fluorescein-labeled cathepsin K-antisense S-ODN in the
culture medium in the presence of Tfx-50 (data not shown; Ref. 26). The
carbaprostacyclin-induced increase in pit area was completely blocked
by 5-20 µM antisense S-ODN of PPAR / (Fig.
5A). Even 20 µM
sense PPAR / S-ODN could not inhibit the increase in pit area
caused by carbaprostacyclin. Neither of the S-ODNs for PPAR /
affected the number of pits on the dentine slices in either control or
carbaprostacyclin-treated cultures (Fig. 5B).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of antisense S-ODN for
PPAR / on the
activation of bone-resorbing activity by carbaprostacyclin in mature
osteoclasts. Highly enriched mature osteoclasts were cultured on
dentine slices with or without carbaprostacyclin (1 × 10 8 M) and with antisense or sense S-ODN for
PPAR / for 20 h. A, antisense S-ODN for
PPAR / blocked the increase in pit area by carbaprostacyclin in
mature osteoclasts. B, pit number was not affected by S-ODNs
for PPAR / in either control or carbaprostacyclin-treated
clutters. Pit area (A) and pit numbers (B) formed
on dentine slices were determined as described under "Materials and
Methods." Values are means ± S.D., n = 4. *,
p < 0.05 compared with each control group. Data are
representative of those obtained in three other independent
experiments.
|
|
To confirm that the antisense S-ODN of PPAR / reduced the
endogenous level of PPAR / expression, we analyzed the PPAR / mRNA expression level in osteoclasts by Northern blotting. Fig. 6 shows that antisense S-ODN for
PPAR / reduced the mRNA level of PPAR / in mature
osteoclasts cultured on plastic dishes. In contrast, the sense S-ODN
for PPAR / had no effect (data not shown).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of antisense S-ODN for
PPAR / on the level of
PPAR / mRNA in
mature osteoclasts. Total RNA was isolated from mature osteoclasts
that were cultured on plastic dishes with or without 10 µM antisense S-ODN for PPAR / for 20 h. Twenty
micrograms of total RNA was applied in each lane. Northern blot
analysis was carried out with 32P-labeled PPAR / and
glyceraldehyde-3-phosphate dehydrogenase (GPDH) cDNAs as
probes, as described under "Materials and Methods." The experiment
was performed four times, and similar results were obtained each
time.
|
|
Prostacyclin also acts through its plasma membrane receptor, IP. To
eliminate the involvement of IP in activation of osteoclast functions
by prostacyclin, we checked the expression of IP mRNA in the cells.
Fig. 7 shows that the typical size (3.5 kb) of IP mRNA was expressed in osteoblastic MC3T3-E1 and stromal
cells but not in the osteoclasts and that small (about 2 kb) and smear transcripts were detected in all cell types.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 7.
Expression of IP receptor mRNA in bone
cells. Total RNA was isolated from osteoblastic cell line
(MC3T3-E1), bone stromal cells, and mature osteoclasts that had been
cultured on plastic dishes, and 20 µg of total RNA was applied
in each lane. Northern blot analysis was carried out using
32P-labeled IP cDNAs as described under "Materials
and Methods." GPDH, glyceraldehyde-3-phosphate
dehydrogenase.
|
|
 |
DISCUSSION |
We cloned the full-length cDNA of rabbit PPAR / from a
mature osteoclast cDNA library. Both the amino acid sequence and
the mRNA transcript sizes of the rabbit PPAR / were highly
conserved with their human and rodent counterparts. Although previous
reports showed that PPAR / mRNA was widely expressed in mouse
organs (22), until now it was unclear whether PPAR mRNA was
expressed in bone tissue. Our data show that PPAR / was more
abundantly expressed in mature osteoclasts than in osteoblasts and
stromal cells, whereas PPAR mRNA was expressed only in the
clonal osteoblastic cells. This cell-specific expression of PPARs in
bone cells may suggest a specific role of each PPAR in a given type of
bone cells.
It is clear that PPARs are activated by arachidonic acid metabolites
such as prostacyclin (prostaglandin I2) and its analogues, i.e. carbaprostacyclin and iloprost (21). The metabolites
produced from arachidonic acid, such as leukotriene and prostaglandin, have complex actions affecting bone metabolism (28, 29). Leukotriene B4, which is one of the 5-lipoxygenase metabolites,
directly activates the bone resorption activity in rat, mouse, and
chicken osteoclasts (30-33). Our data show that mature rabbit
osteoclasts also were activated by leukotriene B4 but that
nuclear leukotriene B4 receptor (PPAR ) mRNA was not
detected in mature rabbit osteoclasts by Northern blot analysis.
However, it was reported that leukotriene B4 binding, which
is considered to reflect the leukotriene B4 receptor,
occurred in mature chicken osteoclasts (30). These data suggest that
leukotriene B4 activates osteoclast function through its
membrane receptor. Leukotriene B4 also inactivates osteoblast-mediated bone formation (34). Thus, 5-lipoxygenase metabolites appear to down-regulate bone formation.
Prostaglandin E2 (PGE2), which is one of the
prostaglandin endoperoxide synthase metabolites, has paradoxical
functions in osteoclasts. PGE2 directly inhibits
bone-resorbing activity in rabbit and rat mature osteoclasts (35, 36).
On the other hand, PGE2 indirectly activates osteoclastic
bone resorption through accessory cells, such as osteoblasts and
stromal cells. Moreover, PGE2 activates mouse osteoclast
differentiation (37, 38) but inactivates human
osteoclast-differentiation (39). These paradoxical functions of
PGE2 may be due to variations in experimental conditions, such as the presence of accessory cells, difference in species of
osteoclasts, and differences in the differentiation stage of the
osteoclasts (40-43).
Previously, it was reported that prostacyclin activated osteoclastic
bone resorption through accessory cells in calvaria cultures (44). On
the other hand, a millimolar level of prostacyclin inhibited the pit
formation by mature osteoclasts (35). Moreover, a high concentration
(2.5 × 10 5 M) of prostacyclin reduced
osteoclastic motility and cell size, whereas low concentrations
(1.5 × 10 7 M) increased osteoclast
motility and cell size in isolated mature osteoclasts (36). Also, our
results show that 1 × 10 5 M
carbaprostacyclin inhibited bone resorption by mature osteoclasts but
that 1 × 10 9 to 1 × 10 8
M carbaprostacyclin activated the cells. These results
indicate a differential effect of various levels of prostacyclin on
mature osteoclasts. These may be due to the action of more than one
type of receptor for prostacyclin in osteoclasts. It is reported that prostacyclin exerts its function through a nuclear receptor
(PPAR / ) and a membrane receptor (IP) (21, 45). The plasma
membrane receptor for prostacyclin, IP, is abundantly expressed in
thymus, lung, heart, and spleen (45, 46). In our present study, typical IP mRNA could not be detected in mature rabbit osteoclasts by Northern blot analysis. These results suggest the possibility of the
existence of some other types of membrane receptor and/or nuclear
receptor for prostacyclin in mature rabbit osteoclast to response to a
high concentration of prostacyclin.
We clearly showed that antisense S-ODN for PPAR / blocked the
induction of osteoclastic bone resorption by carbaprostacyclin. However, antisense and sense S-ODN for PPAR / or carbaprostacyclin did not affect pit formation number on dentine slice. These data indicate that S-ODN for PPAR / does not have any toxic effect on
mature osteoclasts in the concentrations used. We can thus conclude
that PPAR / has a role in regulation of osteoclast function through prostacyclin. This conclusion is also supported by the data
showing that antisense S-ODN for PPAR / reduced the level of
PPAR / mRNA in osteoclasts and that carbaprostacyclin
stimulated an increase in the mRNA levels of several osteoclastic genes.
One of the PPAR subtypes, PPAR , has been implicated as a mediator of
adipocyte and monocyte/macrophage differentiation (47-50). Also, it
was reported that osteoclasts are differentiated from blood stem cells,
especially those of the monocyte/macrophage lineage (1-3). The
transcriptional factor c-Fos mediates osteoclast differentiation but
not macrophage differentiation (51). Another transcriptional factor,
PU. 1, mediates both osteoclast and macrophage differentiation (52). We
cannot exclude the possibility that PPARs play a critical role in
osteoclastogenesis, because we used only mature osteoclasts in all of
our studies.
Our data indicate that PPAR / mRNA but not IP mRNA is
abundantly expressed in mature osteoclasts and that a prostacyclin analogue induced osteoclastic bone resorption in vitro. In
addition, the results of antisense S-ODN analysis support the
involvement of PPAR / in prostacyclin-induced osteoclastic bone
resorption. These data suggest that, in part, the bone loss mediated by
prostacyclin, a metabolite of arachidonic acid, is modulated by
PPAR / in mature osteoclasts.
 |
ACKNOWLEDGEMENTS |
We express our gratitude to Dr. Na N. Yang
(Lilly) for useful comments on the manuscript and to Y. Katagiri and S. Ishii for technical assistance. We also thank Drs. M. Kobori
(Yamanouchi Pharmaceutical Co., Ltd) and H. Kawashima (Nigata
University) for the generous gift of rabbit TRAP cDNA.
 |
FOOTNOTES |
*
This work was supported in part by a grant from the Ministry
of Education, Science, Sports, and Culture of Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence reported in this paper has been submitted
to the DDBJ/GenBankTM/EBI Data Bank with accession
number AB033614.
To whom correspondence should be addressed. Tel.:
81-492-79-2768; Fax: 81-492-71-3523; E-mail:
o-anat-1@dent.meikai.ac.jp.
 |
ABBREVIATIONS |
The abbreviations used are:
TRAP, tartrate-resistant acid phosphatase;
PPAR, peroxisome
proliferator-activated receptor;
S-ODN, phosphothiorate
oligodeoxynucleotide;
MEM, minimal essential medium;
FBS, fetal bovine
serum;
kb, kilobase pair(s);
PGE2, prostaglandin
E2.
 |
REFERENCES |
| 1.
|
Teitelbaum, S. L.,
Abu-Amer, Y.,
and Ross, F. P.
(1995)
J. Cell. Biochem.
59,
1-10[Medline]
[Order article via Infotrieve]
|
| 2.
|
Rifkin, B. R.,
and Gay, C. V.
(1992)
Biology and Physiology of the Osteoclast
, CRC Press, Inc., Boca Raton, FL
|
| 3.
|
Erlebacher, A.,
Filvaroff, E. H.,
Gitelman, S. E.,
and Derynck, R.
(1995)
Cell
80,
371-378[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Yasuda, H.,
Shima, N.,
Nakagawa, N.,
Yamaguchi, K.,
Kinosaki, M.,
Mochizuki, S.,
Tomoyasu, A.,
Yano, K.,
Goto, M.,
Murakami, A.,
Tsuda, E.,
Morinaga, T.,
Higashio, K.,
Udagawa, N,
Takahashi, N.,
and Suda, T.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
3597-3602[Abstract/Free Full Text]
|
| 5.
|
Yasuda, H.,
Shima, N.,
Nakagawa, N.,
Mochizuki, S. I.,
Yano, K.,
Fujise, N.,
Sato, Y.,
Goto, M.,
Yamaguchi, K.,
Kuriyama, M.,
Kanno, T.,
Murakami, A.,
Tsuda, E.,
Morinaga, T.,
and Higashio, K.
(1998)
Endocrinology
139,
1329-1337[Abstract/Free Full Text]
|
| 6.
|
Kodama, H.,
Nose, M.,
Niida, S.,
and Yamasaki, A.
(1991)
J. Exp. Med.
173,
1291-1294[Abstract/Free Full Text]
|
| 7.
|
Fuller, K.,
Owens, J. M.,
and Chambers, T. J.
(1998)
J. Endocrinol.
158,
341-350[Abstract]
|
| 8.
|
Pacifici, R.
(1996)
J. Bone Miner. Res.
11,
1043-1051[Medline]
[Order article via Infotrieve]
|
| 9.
|
Poli, V.,
Balena, R.,
Fattori, E.,
Markatos, A.,
Yamamoto, M.,
Tanaka, H.,
Ciliberto, G.,
Rodan, G. A.,
and Costantini, F.
(1994)
EMBO J.
13,
1189-1196[Medline]
[Order article via Infotrieve]
|
| 10.
|
Tezuka, K.,
Sato, T.,
Kamioka, H.,
Nijweide, P. J.,
Tanaka, K.,
Matsuo, T.,
Ohta, M.,
Kurihara, N.,
Hakeda, Y.,
and Kumegawa, M.
(1992)
Biochem. Biophys. Res. Commun.
186,
911-917[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Kakudo, S.,
Miyazawa, K.,
Kameda, T.,
Mano, H.,
Mori, Y.,
Yuasa, T.,
Nakamaru, Y.,
Shiokawa, M.,
Nagahira, K.,
Tokunaga, S.,
Hakeda, Y.,
and Kumegawa, M.
(1996)
J. Bone Miner. Metab.
14,
129-136[CrossRef]
|
| 12.
|
Mano, H.,
Yuasa, T.,
Kameda, T.,
Miyazawa, K.,
Nakamaru, Y.,
Shiokawa, M.,
Mori, Y.,
Yamada, T.,
Miyata, K.,
Shindo, H.,
Azuma, H.,
Hakeda, Y.,
and Kumegawa, M.
(1996)
Biochem. Biophys. Res. Commun.
223,
637-642[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Kameda, T.,
Mano, H.,
Yuasa, T.,
Mori, Y.,
Miyazawa, K.,
Shiokawa, M.,
Nakamaru, Y.,
Hiroi, E.,
Hiura, K.,
Kameda, A.,
Yang, N. N.,
Hakeda, Y.,
and Kumegawa, M.
(1997)
J. Exp. Med.
186,
489-495[Abstract/Free Full Text]
|
| 14.
|
Saneshige, S.,
Mano, H.,
Tezuka, K.,
Kakudo, S.,
Mori, Y.,
Honda, Y.,
Itabashi, A.,
Yamada, T.,
Miyata, K.,
Hakeda, Y.,
Ishii, J.,
and Kumegawa, M.
(1995)
Biochem. J.
309,
721-724
|
| 15.
|
Mangelsdorf, D. J.,
Thummel, C.,
Beato, M.,
Herrlich, P.,
Schutz, G.,
Umesono, K.,
Blumberg, B.,
Kastner, P.,
Mark, M.,
Chambon, P.,
and Evans, R. M.
(1995)
Cell
83,
835-839[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kamei, Y.,
Xu, L.,
Heinzel, T.,
Torchia, J.,
Kurokawa, R.,
Gloss, B.,
Lin, S. C,
Heyman, R. A.,
Rose, D. W.,
Glass, C. K.,
and Rosenfeld, M. G.
(1996)
Cell
85,
403-414[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Blumberg, B.,
and Evans, R. M.
(1998)
Genes Dev.
12,
3149-3155[Free Full Text]
|
| 18.
|
Devchand, P. R.,
Keller, H.,
Peters, J. M.,
Vazquez, M.,
Gonzalez, F. J.,
and Wahli, W.
(1996)
Nature
384,
39-43[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Forman, B. M.,
Tontonoz, P.,
Chen, J.,
Brun, R. P.,
Spiegelman, B. M.,
and Evans, R. M.
(1995)
Cell
83,
803-812[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Nagy, L.,
Tontonoz, P.,
Alvarez, J. G.,
Chen, H.,
and Evans, R. M.
(1998)
Cell
93,
229-240[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Hertz, R.,
Berman, I.,
Keppler, D.,
and Bar-Tana, J.
(1996)
Eur. J. Biochem.
235,
242-247[Medline]
[Order article via Infotrieve]
|
| 22.
|
Kliewer, S. A.,
Forman, B. M.,
Blumberg, B.,
Ong, E. S.,
Borgmeyer, U.,
Mangelsdorf, D. J.,
Umesono, K.,
and Evans, R. M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7355-7359[Abstract/Free Full Text]
|
| 23.
|
Tezuka, K.,
Tezukam, Y.,
Maejima, A.,
Sato, T.,
Nemoto, K.,
Kamioka, H.,
Hakeda, Y.,
and Kumegawa, M.
(1994)
J. Biol. Chem.
269,
1106-1109[Abstract/Free Full Text]
|
| 24.
|
Tezuka, K.,
Nemoto, K.,
Tezuka, Y.,
Sato, T.,
Ikeda, Y.,
Kobori, M.,
Kawashima, H.,
Eguchi, H.,
Hakeda, Y.,
and Kumegawa, M.
(1994)
J. Biol. Chem.
269,
15006-15009[Abstract/Free Full Text]
|
| 25.
|
Takada, Y.,
Kusuda, M.,
Hiura, K.,
Sato, T.,
Mochizuki, H.,
Nagao, Y.,
Tomura, M.,
Yahiro, M.,
Hakeda, Y.,
Kawashima, H.,
and Kumegawa, M.
(1992)
Bone Miner.
17,
347-359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Inui, T.,
Ishibashi, O.,
Inaoka, T.,
Origane, Y.,
Kumegawa, M.,
Kokubo, T.,
and Yamamura, T.
(1997)
J. Biol. Chem.
272,
8109-8112[Abstract/Free Full Text]
|
| 27.
|
Kobori, M.,
Ikeda, Y.,
Nara, H.,
Kato, M.,
Kumegawa, M.,
Nojima, H.,
and Kawashima, H.
(1998)
Genes Cells
3,
459-475[Abstract]
|
| 28.
|
Donahue, H. J.
(1992)
in
Biology and Physiology of the Osteoclast
(Rifkin, B. R.
, and Gay, C. V., eds)
, pp. 207-222, CRC Press, Inc., Boca Raton, FL
|
| 29.
|
Klein, D. C.,
and Raisz, L.
(1970)
Endocrinology
86,
1436-1440[Abstract/Free Full Text]
|
| 30.
|
Flynn, M. A.,
Qiao, M.,
Garcia, C.,
Dallas, M.,
and Bonewald, L. F.
(1999)
Calcif. Tissue. Int.
64,
154-159[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Garcia, C.,
Boyce, B. F.,
Gilles, J.,
Dallas, M.,
Qiao, M.,
Mundy, G. R.,
and Bonewald, L. F.
(1996)
J. Bone Miner. Res.
11,
1619-1627[Medline]
[Order article via Infotrieve]
|
| 32.
|
Bonewald, L. F.,
Flynn, M.,
Qiao, M.,
Dallas, M. R.,
Mundy, G. R.,
and Boyce, B. F.
(1997)
Adv. Exp. Med. Biol.
433,
299-302[Medline]
[Order article via Infotrieve]
|
| 33.
|
Gallwitz, W. E.,
Mundy, G. R.,
Lee, C. H.,
Qiao, M.,
Roodman, G. D.,
Raftery, M.,
Gaskell, S. J.,
and Bonewald, L. F.
(1993)
J. Biol. Chem.
268,
10087-10094[Abstract/Free Full Text]
|
| 34.
|
Traianedes, K.,
Dallas, M. R.,
Garrett, I. R.,
Mundy, G. R.,
and Bonewald, L. F.
(1998)
Endocrinology
139,
3178-3184[Abstract/Free Full Text]
|
| 35.
|
Chambers, T. J.,
McSheehy, P. M.,
Thomson, B. M.,
and Fuller, K.
(1985)
Endocrinology
116,
234-239[Abstract/Free Full Text]
|
| 36.
|
Adebanjo, O. A.,
Pazianas, M.,
Zaidi, A.,
Shankar, V. S.,
Bascal, Z. A.,
Dacke, C. G.,
Huang, C. L.,
and Zaidi, M. J.
(1994)
Endocrinology
143,
375-381[Abstract/Free Full Text]
|
| 37.
|
Tokushima, T.,
Sato, T.,
Morita, I.,
and Murota, S.
(1997)
Adv. Exp. Med. Biol.
433,
307-309[Medline]
[Order article via Infotrieve]
|
| 38.
|
Sato, T.,
Morita, I.,
Sakaguchi, K.,
Nakahama, K.,
Smith, W. L.,
Dewitt, D. L.,
and Murota, S.
(1996)
J. Bone Miner. Res.
11,
392-400[Medline]
[Order article via Infotrieve]
|
| 39.
|
Roux, S.,
Pichaud, F.,
Quinn, J.,
Lalande, A.,
Morieux, C.,
Jullienne, A.,
and de Vernejoul, M. C.
(1997)
Endocrinology
138,
1476-1482[Abstract/Free Full Text]
|
| 40.
|
Lader, C. S.,
and Flanagan, A. M.
(1998)
Endocrinology
139,
3157-3164[Abstract/Free Full Text]
|
| 41.
|
Collins, D. A.,
and Chambers, T. J.
(1991)
J. Bone Miner. Res.
6,
157-164[Medline]
[Order article via Infotrieve]
|
| 42.
|
Jimi, E.,
Nakamura, I.,
Amano, H.,
Taguchi, Y.,
Tsurukai, T.,
Tamura, M.,
Takahashi, N.,
and Suda, T.
(1996)
Endocrinology
137,
2187-2190[Abstract/Free Full Text]
|
| 43.
|
Fisher, J. E.,
Rogers, M. J.,
Halasy, J. M.,
Luckman, S. P.,
Hughes, D. E.,
Masarachia, P. J.,
Wesolowski, G.,
Russell, R. G.,
Rodan, G. A.,
and Reszka, A. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
133-138[Abstract/Free Full Text]
|
| 44.
|
Walenga, R. W.,
and Bergstrom, W.
(1985)
Prostaglandins
29,
191-202[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Namba, T.,
Oida, H.,
Sugimoto, Y.,
Kakizuka, A.,
Negishi, M.,
Ichikawa, A.,
and Narumiya, S.
(1994)
J. Biol. Chem.
269,
9986-9992[Abstract/Free Full Text]
|
| 46.
|
Boie, Y.,
Rushmore, T. H.,
Darmon-Goodwin, A.,
Grygorczyk, R.,
Slipetz, D. M.,
Metters, K. M.,
and Abramovitz, M.
(1994)
J. Biol. Chem.
269,
12173-12178[Abstract/Free Full Text]
|
| 47.
|
Manolagas, S. C.
(1995)
Bone
17,
63-67[Medline]
[Order article via Infotrieve]
|
| 48.
|
Tontonoz, P.,
Nagy, L.,
Alvarez, J. G.,
Thomazy, V. A.,
and Evans, R. M.
(1998)
Cell
93,
241-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Spiegelman, B. M.
(1998)
Cell
93,
153-155[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Berger, J.,
Leibowitz, M. D.,
Doebber, T. W.,
Elbrecht, A.,
Zhang, B.,
Zhou, G.,
Biswas, C.,
Cullinan, C. A.,
Hayes, N. S.,
Li, Y.,
Tanen, M.,
Ventre, J.,
Wu, M. S.,
Berger, G. D.,
Mosley, R.,
Marquis, R.,
Santini, C.,
Sahoo, S. P.,
Tolman, R. L.,
Smith, R. G.,
and Moller, D. E.
(1999)
J. Biol. Chem.
274,
6718-6725[Abstract/Free Full Text]
|
| 51.
|
Grigoriadis, A. E.,
Wang, Z. Q.,
Cecchini, M. G.,
Hofstetter, W.,
Felix, R.,
Fleisch, H. A.,
and Wagner, E. F.
(1994)
Science
266,
443-448[Abstract/Free Full Text]
|
| 52.
|
Tondravi, M. M.,
McKercher, S. R.,
Anderson, K.,
Erdmann, J. M.,
Quiroz, M.,
Maki, R.,
and Teitelbaum, S. L.
(1997)
Nature
386,
81-84[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. R. Burch, K. Zhou, L. A. Donnelly, A. S. F. Doney, J. Brady, C. Goddard, A. D. Morris, M. K. Hansen, and C. N. A. Palmer
A Single Nucleotide Polymorphism on Exon-4 of the Gene Encoding PPAR{delta} Is Associated with Reduced Height in Adults and Children
J. Clin. Endocrinol. Metab.,
July 1, 2009;
94(7):
2587 - 2593.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nadra, S. I. Anghel, E. Joye, N. S. Tan, S. Basu-Modak, D. Trono, W. Wahli, and B. Desvergne
Differentiation of Trophoblast Giant Cells and Their Metabolic Functions Are Dependent on Peroxisome Proliferator-Activated Receptor {beta}/{delta}
Mol. Cell. Biol.,
April 15, 2006;
26(8):
3266 - 3281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Caldari-Torres, C. Rodriguez-Sallaberry, E. S. Greene, and L. Badinga
Differential effects of n-3 and n-6 fatty acids on prostaglandin F2alpha production by bovine endometrial cells.
J Dairy Sci,
March 1, 2006;
89(3):
971 - 977.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Balaguer, R. A. Pershing, C. Rodriguez-Sallaberry, W. W. Thatcher, and L. Badinga
Effects of Bovine Somatotropin on Uterine Genes Related to the Prostaglandin Cascade in Lactating Dairy Cows
J Dairy Sci,
February 1, 2005;
88(2):
543 - 552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E. O. Muscat
The Peroxisome Proliferator-Activated Receptor {beta}/{delta} Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells
Mol. Endocrinol.,
December 1, 2003;
17(12):
2477 - 2493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Vosper, L. Patel, T. L. Graham, G. A. Khoudoli, A. Hill, C. H. Macphee, I. Pinto, S. A. Smith, K. E. Suckling, C. R. Wolf, et al.
The Peroxisome Proliferator-activated Receptor delta Promotes Lipid Accumulation in Human Macrophages
J. Biol. Chem.,
November 16, 2001;
276(47):
44258 - 44265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kojima, A. Nemoto, T. Uemura, R. Honma, M. Ogura, and Y.-k. Liu
rDRAK1, a Novel Kinase Related to Apoptosis, Is Strongly Expressed in Active Osteoclasts and Induces Apoptosis
J. Biol. Chem.,
May 25, 2001;
276(22):
19238 - 19243.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|